Designed for adults 18 and older, SleepioRx complements standard care by delivering cognitive behavioral therapy for insomnia via a prescription device. This 90-day treatment adapts to individual symptoms, offering daily sleep tracking and on-the-spot therapeutic content to assist with sleep.
“The FDA’s clearance of SleepioRx is a landmark milestone for Big Health, providing accessible, guideline-recommended, first-line treatment for insomnia,” Big Health CEO Yael Berman said in the Aug. 8 release. “This clearance, coupled with the new proposed reimbursement codes, will for the first time motivate U.S. healthcare providers to prescribe safe and effective treatment alternatives to traditional medication.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.